BeiGene Announces Data on BRUKINSA® (Zanubrutinib) from Phase 2 Trial in Marginal Zone Lymphoma and Phase 3 Trial in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 62nd ASH Annual Meeting

⋮

← $

X Mark channel Not-Safe-For-Work? cancel confirm NSFW Votes: (0 votes)

X Are you the publisher? Claim or contact us about this channel.

X 0

X Search

Sharing:

Title:

URL:

Copy Share URL